ValuEngine downgraded shares of Alimera Sciences, Inc. (NASDAQ:ALIM) from a hold rating to a sell rating in a research report released on Thursday morning.

Several other equities analysts also recently commented on ALIM. Zacks Investment Research upgraded Alimera Sciences from a sell rating to a hold rating in a research note on Thursday, March 30th. Rodman & Renshaw started coverage on Alimera Sciences in a research note on Thursday, April 27th. They issued a buy rating and a $4.00 price objective on the stock. HC Wainwright set a $5.00 price objective on Alimera Sciences and gave the company a buy rating in a research note on Tuesday, July 11th. Finally, Cowen and Company reiterated a buy rating and issued a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $3.38.

Shares of Alimera Sciences (ALIM) opened at 1.47 on Thursday. Alimera Sciences has a 52-week low of $1.03 and a 52-week high of $2.40. The stock has a 50 day moving average price of $1.41 and a 200-day moving average price of $1.38. The firm’s market capitalization is $95.40 million.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The company had revenue of $6.62 million during the quarter, compared to analyst estimates of $8.80 million. During the same quarter last year, the firm posted ($0.22) EPS. The company’s revenue was up 14.1% compared to the same quarter last year. Equities analysts forecast that Alimera Sciences will post ($0.21) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Alimera Sciences, Inc. (ALIM) Lowered to Sell at ValuEngine” was published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at

An institutional investor recently raised its position in Alimera Sciences stock. KCG Holdings Inc. increased its stake in Alimera Sciences, Inc. (NASDAQ:ALIM) by 127.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 78,604 shares of the biopharmaceutical company’s stock after buying an additional 43,977 shares during the period. KCG Holdings Inc.’s holdings in Alimera Sciences were worth $110,000 as of its most recent SEC filing. Institutional investors own 43.58% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.